share_log

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Benzinga ·  05:52  · Ratings

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment